Gossamer Bio aims to file a New Drug Application (NDA) for its drug seralutinib by September 2026, with a potential approval anticipated in the third quarter of 2027.

Several companies, including TOYO, Gossamer Bio, and Baidu, have released their first-quarter earnings reports, showing a mix of results. Some companies beat analyst expectations for EPS or revenue, while others missed.

Despite a recent setback with PROSERA, bullish analysts continue to see significant upside potential for Gossamer Bio (GOSS) stock.

Options trading for Gossamer Bio suggests an implied 46.1% movement in the company's share price following its upcoming earnings report.

Gossamer Bio's shares fell following the announcement of a larger-than-anticipated first-quarter loss, despite the company beating revenue expectations.

Despite a setback in its Phase 3 trials, analysts continue to hold a bullish outlook on Gossamer Bio, indicating long-term confidence in the company.

Gossamer Bio (GOSS) stock is experiencing a continued downtrend, even as the company reports impressive revenue figures, indicating investor concerns beyond top-line growth.

Gossamer Bio's experimental drug for a lung condition has reportedly failed in its late-stage clinical trial, impacting the company's prospects.

Cantor Fitzgerald has downgraded its rating for Gossamer Bio (GOSS) to Neutral.

Gossamer Bio has been downgraded by Cantor, citing an unclear regulatory path for its drug seralutinib as the reason for the revised outlook.